BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 14506194)

  • 1. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison.
    Brouwers AH; Buijs WC; Oosterwijk E; Boerman OC; Mala C; De Mulder PH; Corstens FH; Mulders PF; Oyen WJ
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3953S-60S. PubMed ID: 14506194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy.
    Steffens MG; Boerman OC; Oyen WJ; Kniest PH; Witjes JA; Oosterhof GO; van Leenders GJ; Debruyne FM; Corstens FH; Oosterwijk E
    Cancer Res; 1999 Apr; 59(7):1615-9. PubMed ID: 10197637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250.
    Steffens MG; Boerman OC; Oosterwijk-Wakka JC; Oosterhof GO; Witjes JA; Koenders EB; Oyen WJ; Buijs WC; Debruyne FM; Corstens FH; Oosterwijk E
    J Clin Oncol; 1997 Apr; 15(4):1529-37. PubMed ID: 9193349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response.
    Brouwers AH; Buijs WC; Mulders PF; de Mulder PH; van den Broek WJ; Mala C; Oosterwijk E; Boerman OC; Corstens FH; Oyen WJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7178s-7186s. PubMed ID: 16203819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
    van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250.
    Steffens MG; Boerman OC; de Mulder PH; Oyen WJ; Buijs WC; Witjes JA; van den Broek WJ; Oosterwijk-Wakka JC; Debruyne FM; Corstens FH; Oosterwijk E
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3268s-3274s. PubMed ID: 10541374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic model of iodine-131-G250 antibody in renal cell carcinoma patients.
    Loh A; Sgouros G; O'Donoghue JA; Deland D; Puri D; Capitelli P; Humm JL; Larson SM; Old LJ; Divgi CR
    J Nucl Med; 1998 Mar; 39(3):484-9. PubMed ID: 9529296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Technology evaluation: WX-G250, Wilex/Ludwig Institute for Cancer Research.
    Kennett RH
    Curr Opin Mol Ther; 2003 Feb; 5(1):70-5. PubMed ID: 12669474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.
    Bleumer I; Knuth A; Oosterwijk E; Hofmann R; Varga Z; Lamers C; Kruit W; Melchior S; Mala C; Ullrich S; De Mulder P; Mulders PF; Beck J
    Br J Cancer; 2004 Mar; 90(5):985-90. PubMed ID: 14997194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients.
    Varga Z; de Mulder P; Kruit W; Hegele A; Hofmann R; Lamers C; Warnaar S; Mala C; Ullrich S; Mulders P
    Folia Biol (Praha); 2003; 49(2):74-7. PubMed ID: 12779016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
    van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma.
    Brouwers AH; Mulders PF; de Mulder PH; van den Broek WJ; Buijs WC; Mala C; Joosten FB; Oosterwijk E; Boerman OC; Corstens FH; Oyen WJ
    J Clin Oncol; 2005 Sep; 23(27):6540-8. PubMed ID: 16170161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats.
    Brouwers A; Verel I; Van Eerd J; Visser G; Steffens M; Oosterwijk E; Corstens F; Oyen W; Van Dongen G; Boerman O
    Cancer Biother Radiopharm; 2004 Apr; 19(2):155-63. PubMed ID: 15186595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity.
    Liu Z; Smyth FE; Renner C; Lee FT; Oosterwijk E; Scott AM
    Cancer Immunol Immunother; 2002 May; 51(3):171-7. PubMed ID: 11941456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.
    Davis ID; Wiseman GA; Lee FT; Gansen DN; Hopkins W; Papenfuss AT; Liu Z; Moynihan TJ; Croghan GA; Adjei AA; Hoffman EW; Ingle JN; Old LJ; Scott AM
    Cancer Immun; 2007 Aug; 7():13. PubMed ID: 17705349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial.
    Divgi CR; Pandit-Taskar N; Jungbluth AA; Reuter VE; Gönen M; Ruan S; Pierre C; Nagel A; Pryma DA; Humm J; Larson SM; Old LJ; Russo P
    Lancet Oncol; 2007 Apr; 8(4):304-10. PubMed ID: 17395103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.
    Bauer S; Oosterwijk-Wakka JC; Adrian N; Oosterwijk E; Fischer E; Wüest T; Stenner F; Perani A; Cohen L; Knuth A; Divgi C; Jäger D; Scott AM; Ritter G; Old LJ; Renner C
    Int J Cancer; 2009 Jul; 125(1):115-23. PubMed ID: 19384924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
    Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
    J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.